Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443062 | PMC |
| http://dx.doi.org/10.1007/s00401-020-02127-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.
Neuro Oncol
August 2024
Department of Pathology and Neurological Surgery, UCSF, San Francisco, CA, USA.
Article Synopsis
- - Meningiomas are the most common primary brain tumors and are significant in neuropathology, with the 2021 WHO Classification introducing new molecular markers for their grading, particularly regarding TERT promoter changes and CDKN2A/B deletions for grade 3 tumors.
- - The cIMPACT-NOW Steering Committee formed a working group post-publication to clarify existing grading questions and assess new research that wasn't included in the 2021 classification, focusing on improving standards for diagnosing meningiomas.
- - The update suggests more standardized evaluations for brain invasion, recommends advanced molecular testing in certain situations, and introduces a potential grade 2 classification for some cases with specific chromosomal deletions, while acknowledging that some areas still need
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.
Ann Afr Med
July 2024
Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Kalyani, West Bengal, India.
The fifth edition of the WHO classification of tumors of the central nervous system (WHO CNS5) was published in 2021 which is the sixth version of the international standard for the diagnostics of CNS tumors. Regular updates of the consortium to inform molecular and practical approaches to CNS tumor taxonomy (cIMPACT-NOW) shaped the WHO CNS5 which continues the trend of incorporating the molecular characteristics of tumors into the histological and immunohistochemical findings. The various updates can be classified into general changes across all tumors and specific changes within the tumor groups.
View Article and Find Full Text PDFOptimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience.
Sci Rep
November 2023
Molecular Medicine Laboratory, Centro di Ricerche Emato-Oncologiche (C.R.E.O.), S. Maria Della Misericordia Hospital, University of Perugia, Piazzale Menghini 9, 06132, Perugia, Italy.
Our work reports implementation of a useful genetic diagnosis for the clinical managment of patients with astrocytic tumors. We investigated 313 prospectively recruited diffuse astrocytic tumours by applying the cIMPACT-NOW Update 3 signature. The cIMPACT-NOW Update 3 (cIMPACT-NOW 3) markers, i.
View Article and Find Full Text PDFClassification and Grading of Central Nervous System Tumors According to the World Health Organization 5th Edition.
Semin Neurol
December 2023
Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
The World Health Organization (WHO) released the 5th edition of its classification of central nervous system (CNS) tumors in 2021. Advances in the landscape of molecular tumor pathophysiology prompted major revisions to the previous edition released in 2016, some of which were first introduced by the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW). The 2021 classification system integrates newly gained molecular insights to guide changes in tumor taxonomy and nomenclature, introduces several new types of tumors, and expands the use of molecular testing for diagnosis and grading, with a particular impact on adult-type and pediatric-type gliomas, ependymomas, and embryonal tumors.
View Article and Find Full Text PDF[World Health Organization Classification of Central Nervous System Tumours, 5 Edition:Points of the Update and the Current Status].
No Shinkei Geka
March 2023
Department of Brain Disease Translational Research, Graduate School of Medicine, Juntendo University.
The World Health Organization Classification of the Tumours, 5 Edition Central Nervous System Tumours(WHO CNS5), has undergone ground-breaking changes in collaboration with cIMPACT-NOW(the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). Tumors are now classified and named according to the tumor type alone, and the tumor grading is defined within each tumor type. CNS WHO grading is based on either histological or molecular criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!